Prothena Corp Public Ltd Co (PRTA) stock
PRTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3017% below fair value
$8.16−0.07 (-0.85%)
Close on Nov 13, 2026Market cap $418.91MP/E –Yield –
Prothena Corp Public price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Prothena Corp Public's price to sales ratio was 8.3× on Nov 11, 2026, against 49.1× a year earlier. Over the last 5 years it ranged from 1.8× to 66.1×, with a median of 11.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 8.3× | −35.3 |
| 2025 | Dec 31, 2025 | 43.6× | +38.0 |
| 2024 | Dec 31, 2024 | 5.6× | −8.2 |
| 2023 | Dec 29, 2023 | 13.8× | −6.3 |
| 2022 | Oct 31, 2022 | 20.1× | +8.6 |
| 2021 | Dec 31, 2021 | 11.5× | −441.2 |
| 2019 | Oct 31, 2019 | 452.7× | +37.9 |
| 2018 | Dec 31, 2018 | 414.7× | +362.3 |
| 2017 | Dec 29, 2017 | 52.5× | −318.1 |
| 2016 | Jan 29, 2016 | 370.6× | +0.7 |
| 2015 | Oct 30, 2015 | 369.9× | +358.3 |
| 2014 | Dec 31, 2014 | 11.6× | – |
See a number that looks wrong?